Figure 6From: Treatment with lamivudine versus lamivudine and thymosin alpha-1 for e antigen-positive chronic hepatitis B patients: a meta-analysisAnalysis of the HBeAg seroconversion rate at the end of 12 months follow-up between lamivudine and thymosin versus lamivudine groups.Back to article page